(Allianz News) – GENinCode PLC announced on Tuesday that the UK’s National Health Service has allocated funding to increase the use of polygenic testing for heart disease.
GENinCode shares were up 10% at 16.00 pence each in London afternoon Tuesday.
The Manchester-based biotech said the NHS budget will accelerate the use of GENinCode’s Lipid inCode test to detect and treat hereditary high cholesterol to prevent cardiovascular disease.
GENinCode said LipidInCode is the first commercial polygenic test aimed at preventing cardiovascular disease to be implemented by the NHS, and the expanded use supports the NHS’s ten-year plan to identify at least 25% of people with familial hypercholesterolaemia by 2024.
The company added that the expansion is in collaboration with the Academic Health Sciences Network for the North East and North Cumbria in England to use the Lipid InCot test in primary care.
Matthew Walls, chief executive of GENinCode, said: “We look forward to helping the NHS achieve its long-term goal of identifying patients with hypercholesterolaemia and providing earlier risk assessment of cardiovascular disease to improve health outcomes.
By Sabrina Bendy; Journalist at Alliance News
Comments and questions to [email protected]
Copyright 2023 Alliance News Limited. All rights reserved.
“Certified food fanatic. Extreme internet guru. Gamer. Evil beeraholic. Zombie ninja. Problem solver. Unapologetic alcohol lover.”
Sweden announced agreement between EU countries on asylum reform
Australia: Qantas Airlines Abandons Gender Uniforms
For the first time in the United States, Donald Trump has been indicted by a federal judge